Publications 2015

Abba M., Benner A., Patil N., Heil O., Allgayer H.:  Differentially expressed microRNAs in colorectal cancer metastasis. Genomics Data 6 33-35, 2015.

Afshar-Oromieh A., Avtzi E., Giesel F.L., Holland-Letz T., Linhart H.G., Eder M., Eisenhut M., Boxler S., Hadaschik B.A., Kratochwil C., Weichert W., Kopka K., Debus J., Haberkorn U.:  The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur.J.Nucl.Med.Mol.Imag. 42 (2) 197-209, 2015.

Afshar-Oromieh A., Hetzheim H., Kratochwil C., Benesova M., Eder M., Neels O.C., Eisenhut M., Kübler W., Holland-Letz T., Giesel F.L., Mier W., Kopka K., Haberkorn U.:  The theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J.Nucl.Med. 56 (11) 1697-1705, 2015.

Akram I.G., Georges R., Hielscher T., Adwan H., Berger M.R.:  The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumor Biol. (epub) , 2015.

Aschauer L., Limonciel A., Stanzel S., Kopp-Schneider A., Hewitt P., Lukas A., Leonard M.O., Pfaller W., Jennings P.:  Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. Toxicol.in Vitro 30 (1) 106-116, 2015.

Balss J., Thiede C., Bochtler T., Okun J.G., Saadati M., Benner A., Pusch S., Ehninger G., Schaich M., Ho A.D., von Deimling A., Krämer A., Heilig C.E.:  Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukem. (epub) , 2015.

Bergmann L., Maute L., Heil G., Rüssel J., Weidmann E., Köberle D., Fuxius S., Weigang-Köhler K., Aulitzky W.E., Wörmann B., Hartung G., Moritz B., Edler L., Burkholder I., Scheulen M.E., Richly H.:  A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur.J.Cancer 51 (1) 27-36, 2015.

Blume C.J., Hotz-Wagenblatt A., Hüllein J., Sellner L., Jethwa A., Stolz T., Slabicki M., Lee K., Sharathchandra A., Benner A., Dietrich S., Oakes C.C., Dreger P., Te Raa D., Kater A.P., Jauch A., Merkel O., Oren M., Hielscher T., Zenz T.:  p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukem. 29 (10) 2015-2023, 2015.

Bochtler T., Hegenbart U., Kunz C., Benner A., Schönberg S.O.:  Reply to R. Warsame et al. J.Clin.Oncol. 33 (33) 3976-3977, 2015.

Bochtler T., Hegenbart U., Kunz C., Granzow M., Benner A., Seckinger A., Kimmich C., Goldschmidt H., Ho A.D., Hose D., Jauch A., Schönland S.O.:  Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with Bortezomib-based regimens. J.Clin.Oncol. 33 (12) 1371-1378, 2015.

Breitkreutz I., Becker N., Benner A., Kosely F., Heining C., Hillengass J., Egerer G., Ho A.D., Goldschmidt H., Raab M.S.:  Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol.Oncol. (epub) , 2015.

Busch K., Klapproth K., Barile M., Flossdorf M., Holland-Letz T., Schlenner S.M., Reth M., Höfer T., Rodewald H.R.:  Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. Nature 518 542-546, 2015.

Chen H., Zucknick M., Werner S., Brenner H.:  Head-to-head comparison and evaluation of 92 plasma protein biomarkers for early detection of colorectal cancer in a true screening setting. Clin.Cancer Res. 21 (14) 3318-3326, 2015.

Cheng P., Phillips E., Kim S.H., Taylor D., Hielscher T., Puccio L., Hjelmeland A.B., Lichter P., Nakano I., Goidts V.:  Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Rep. 4 (5) 899-913, 2015.

Dietrich S., Radujkovic A., Stölzel F., Falk C.S., Benner A., Schaich M., Bornhäuser M., Ehninger G., Krämer A., Hegenbart U., Ho A.D., Dreger P., Luft T.:  Pretransplant metabolic distress predicts relapse of acute myeloid leukemia after allogeneic stem cell transplantation. Transplantat. 99 (5) 1065-1071, 2015.

Dubash T.D., Hoffmann C.M., Oppel F., Giessler K.M., Bergmann S., Dieter S.M., Hüllein J., Zenz T., Herbst F., Scholl C., Weichert W., Werft W., Benner A., Schmidt M., Schneider M., Glimm H., Ball C.R.:  Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett. (epub) , 2015.

Echterdiek F., Janikovits J., Staffa L., Müller M., Lahrmann B., Frühschütz M., Hartog B., Nelius N., Benner A., Tariverdian M., von Knebel-Döberitz M., Grabe N., Kloor M.:  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunol. (epub) , 2015.

Ecker J., Öhme I., Mazitschek U., Korshunov A., Kool M., Hielscher T., Kiss J., Selt F., Konrad C., Lodrini M., Deubzer H.E., von Deimling A., Kulozik A., Pfister S.M., Witt O., Milde T.:  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol.Commun. 3 22, 2015.

Gebhardt C., Sevko A., Jiang H., Lichtenberger R., Reith M., Tarnanidis K., Holland-Letz T., Umansky V., Beckhove P., Sucker A., Schadendorf D., Utikal J., Umansky V.:  Myeloid cells and related chronic Inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin.Cancer Res. 21 5407, 2015.

Göppert B., Frauenschuh L., Zucknick M., Rössler S., Mehrabi A., Hafezi M., Stenzinger A., Warth A., Pathil A., Renner M., Schirmacher P., Weichert W.:  Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br.J.Cancer 113 (9) 1343-1349, 2015.

Habl G., Katayama S., Uhl M., Kessel K.A., Edler L., Debus J., Herfarth K., Sterzing F.:  Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate - first results of the PLATIN 1 trial. BMC Cancer 15 (1) 868, 2015.

Hahn M., Schnitzler P., Schweiger B., Kunz C., Ho A.D., Goldschmidt H., Schmitt M.:  Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 100 (7) E285-E288, 2015.

Hamon J., Renner M., Jamei M., Lukas A., Kopp-Schneider A., Bois F.Y.:  Quantitative invitro to invivo extrapolation of tissues toxicity. Toxicol.in Vitro 30 (1 PART A) 203-216, 2015.

Hanna B.S., McClanathan F., Yazdanparast H., Zaborsky N., Kalter V., Rößner P.M., Benner A., Dürr C., Egle A., Gribben J.G., Lichter P., Seiffert M.:  Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukem. (epub) , 2015.

Häfner M.F., Röder F., Sterzing F., Krug D., Körber S.A., Kappes J., Hoffmann H., Slynko A., Debus J., Bischof M.:  Postoperative radiotherapy of patients with thymic epithelial tumors (TET). A retrospective analysis of outcome and toxicity. Strahlenther.Onkol. 191 (2) 133-140, 2015.

Heim S., Sill M., Jones D.T., Vasiljevic A., Jouvet A., Fevre-Montange M., Wesseling P., Beschorner R., Mittelbronn M., Kohlhof P., Hovestadt V., Johann P., Kool M., Pajtler K.W., Korshunov A., Ruland V., Sperveslage J., Thomas.C., Witt H., von Deimling A., Paulus W., Pfister S.M., Capper D., Hasselblatt M.:  Papillary tumor of the pineal region: a distinct molecular entity. Brain Pathol. (epub) , 2015.

Hildebrandt W., Sauer R., Bonaterra G., Dugi K.A., Edler L., Kinscherf R.:  Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. Am.J.Clin.Nutr. 102 (5) 1014-1025, 2015.

Hillengass J., Stoll J., Zechmann C.M., Kunz C., Wagner B., Heiss C., Sumkauskaite M., Möhler T.M., Schlemmer H.P., Goldschmidt H., Delorme S.:  The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur.Radiol. 25 (3) 745-750, 2015.

Holland-Letz T., Kopp-Schneider A.:  Optimal experimental designs for dose-response studies with continuous endpoints. Arch.Toxicol. 89 (11) 2059-2068, 2015.

Jiang X., Kopp-Schneider A.:  Statistical strategies for averaging EC50 from multiple dose-response experiments. Arch.Toxicol. 89 (11) 2119-2127, 2015.

Kap E.J., Seibold P., Richter S., Scherer D., Habermann N., Balavarca Y., Jansen L., Becker N., Pfütze K., Popanda O., Hoffmeister M., Ulrich A., Benner A., Ulrich C.M., Burwinkel B., Brenner H., Chang-Claude J.:  Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer. Pharmacogen.J. 15 (6) 505-512, 2015.

Kratochwil C., Stefanova M., Mavriopoulou E., Holland-Letz T., Dimitrakopoulou-Strauss A., Afshar-Oromieh A., Mier W., Haberkorn U., Giesel F.:  SUV of 68Ga-DOTATOC PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol.Imag.Biol. 17 (3) 313-318, 2015.

Lelgemann M., Wild C., Antes G., Edler L., Ernst E., Gärtner J., Schmacke N.:  Unsustainable claims. (Leserbrief zu: Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe. A randomized controlled trial. Dtsch.Arztebl.Int. 111, 493-502, 2014) Dtsch.Arztebl.Int. 112 10-11, 2015.

Limonciel A., Moenks K., Stanzel S., Truisi G.L., Parmentier C., Aschauer L., Wilmes A., Richert L., Hewitt P., Müller S.O., Lukas A., Kopp-Schneider A., Leonard M.O., Jennings P.:  Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol.in Vitro 30 (1 PART A) 7-18, 2015.

Mai E.K., Bertsch U., Dürig J., Kunz C., Haenel M., Blau I.W., Munder M., Jauch A., Schurich B., Hielscher T., Merz M., Hügle-Dörr B., Seckinger A., Hose D., Hillengass J., Raab M.S., Neben K., Lindemann H.W., Zeis M., Gerecke C., Schmidt-Wolf I.G., Weisel K., Scheid C., Salwender H., Goldschmidt H.:  Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma. Leukem. 29 1721-1729, 2015.

Mai E.K., Hielscher T., Kloth J.K., Merz M., Shah S., Raab M.S., Hillengass M., Wagner B., Jauch A., Hose D., Weber M.A., Delorme S., Goldschmidt H., Hillengass J.:  A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 100 (6) 818-825, 2015.

Meissner J., Tichy D., Katzke V., Kühn T., Dietrich S., Schmitt T., Ziepert M., Kuhnt E., Rixecker T., Zorn M., Witzens-Harig M., Pfreundschuh M., Ho A.D.:  Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Ann.Oncol. 26 (8) 1771-1776, 2015.

Merz M., Möhler M., Ritsch J., Bäuerle T., Zechmann C., Wagner B., Jauch A., Hose D., Kunz C., Hielscher T., Laue H., Goldschmidt H., Delorme S., Hillengass J.:  Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur.Radiol. (epub) , 2015.

Merz M., Salwender H., Hänel M., Mai E.K., Bertsch U., Kunz C., Hielscher T., Blau I.W., Scheid C., Hose D., Seckinger A., Jauch A., Hillengass J., Raab M.S., Schurich B., Munder M., Schmidt-Wolf I.G., Gerecke C., Lindemann H.W., Zeis M., Weisel K., Dürig J., Goldschmidt H.:  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica 100 (7) 964-969, 2015.

Merz M., Ritsch J., Kunz C., Wagner B., Sauer S., Hose D., Möhler T., Delorme S., Goldschmidt H., Zechmann C., Hillengass J.:  Dynamic contrast-enhanced magnetic resonance imaging for assessment of anti-angiogenic treatment effects in multiple myeloma. Clin.Cancer Res. 21 (1) 106-112, 2015.

Mudduluru G., Abba M., Batliner J., Patil N., Scharp M., Lunavat T.R., Leupold J.H., Oleksiuk O., Juraeva D., Thiele W., Rothley M., Benner A., Ben-Neriah Y., Sleeman J., Allgayer H.:  A systematic approach to defining the microRNA landscape in metastasis. Cancer Res. 75 (15) 3010-3019, 2015.

Owsijewitsch M., Ley-Zaporozhan J., Kuhnigk J.M., Kopp-Schneider A., Eberhardt R., Eichinger M., Heussel C.P., Kauczor H.U., Ley S.:  Quantitative emphysema distribution in anatomic and non-anatomic lung regions. COPD 12 (3) 257-266, 2015.

Pajtler K.W., Witt H., Sill M., Jones D.T., Hovestadt V., Kratochwil F., Wani K., Tatevossian R., Punchihewa C., Johann P., Reimand J., Warnatz H.J., Ryzhova M., Mack S., Ramaswamy V., Capper D., Schweizer L., Sieber L., Wittmann A., Huang Z., van Sluis P., Volckmann R., Koster J., Versteeg R., Fults D., Toledano H., Avigad S., Hoffmann L.M., Donson A.M., Foreman N., Hewer E., Zitterbart K., Gilbert M., Armstrong T.S., Gupta N., Allen J.C., Karajannis M.A., Zagzag D., Hasselblatt M., Kulozik A.E., Witt O., Collins V.P., Hoff K.v., Rutkowski S., Pietsch T., Bader G., Yaspo M.L., Deimling A.v., Lichter P., Taylor M.D., Gilbertson R., Ellison D.W., Aldape K., Korshunov A., Kool M., Pfister S.M.:  Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 (5) 728-743, 2015.

Pfeifer M., Hertwig F., Röls F., Dreidax D., Gartlgruber M., Menon R., Krämer A., Roncaioli J.L., Sand F., Heuckmann J.M., Ikram F., Schmidt R., Ackermann S., Engesser A., Kahlert Y., Vogel W., Altmüller J., Nürnberg P., Thierry-Mieg J., Mariappan A., Heynck S., Mariotti E., Henrich K.O., Glöckner C., Bosco G., Leuschner I., Schweiger M.R., Savelyeva L., Watkins S.C., Shao C., Bell E., Höfer T., Achter V., Lang U., Theissen J., Volland R., Saadati M., Eggert A., de Wilde B., Berthold F., Peng Z., Zhao C., Shi L., Ortmann M., Büttner R., Perner S., Hero B., Schramm A., Schulte J.H., Herrmann C., O'Sullivan R.J., Westermann F., Thomas R.K., Fischer M.:  Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526 (7575) 700-704, 2015.

Pfütze K., Benner A., Hoffmeister M., Jansen L., Yang R., Bläker H., Herpel E., Ulrich A., Ulrich C.M., Chang-Claude J., Brenner H., Burwinkel B.:  Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics 106 (6) 348-354, 2015.

Radujkovic A., Becker N., Benner A., Penack O., Platzbecker U., Stölzel F., Bornhäuser M., Hegenbart U., Ho A.D., Dreger P., Luft T.:  Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. Oncotarget 6 (33) 35095-35106, 2015.

Reissfelder C., Stamova S., Gossmann C., Braun M., Bonertz A., Walliczek U., Grimm M., Rahbari N.N., Koch M., Saadati M., Benner A., Büchler M.W., Jäger D., Halama N., Khazaie K., Weitz J., Beckhove P.:  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J.Clin.Invest. 125 (2) 739-751, 2015.

Rettig I., Koeneke E., Trippel F., Mueller W.C., Burhenne J., Kopp-Schneider A., Fabian J., Schober A., Fernekorn U., Deimling A.v., Deubzer H.E., Milde T., Witt O., Öhme I.:  Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis. 6 e1657, 2015.

Safi S., Benner A., Walloscheck J., Renner M., op den Winkel J., Muley T., Storz K., Dienemann H., Hoffmann H., Schneider T.:  Development and validation of a risk score for predicting death after pneumonectomy. PLoS_ONE 10 (4) e0121295, 2015.

Savary C.C., Jiang X., Aubry M., Josse R., Kopp-Schneider A., Hewitt P., Guillouzo A.:  Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol.in Vitro 30 (1 PART A) 27-35, 2015.

Schrader C.H., Kolb M., Zaoui K., Flechtenmacher C., Grabe N., Weber K.J., Hielscher T., Plinkert P., Hess J.:  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol.Cancer 14 107, 2015.

Selt F., Deiss A., Korshunov A., Capper D., Witt H., van Tilburg C.M., Jones D.T., Witt R., Sahm F., Reuss D., Kolsche C., Ecker J., Öhme I., Hielscher T., von Deimling A., Kulozik A.E., Pfister S.M., Witt O., Milde T.:  Pediatric targeted therapy: Clinical feasibility of personalized diagnostics in children with relapsed and progressive tumors. Brain Pathol.  2015.

Shukla K., Sharma A.K., Ward A., Will R., Hielscher T., Balwierz A., Breunig C., Münstermann E., König R., Keklikoglou I., Wiemann S.:  MicroRNA-30c-2-3p negatively regulates NF-?B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Mol.Oncol. 9 (6) 1106-1119, 2015.

Sill M., Saadati M., Benner A.:  Applying stability selection to consistently estimate sparse principal components in high-dimensional molecular data. Bioinformat. 31 (16) 2683-2690, 2015.

Staffa L., Echterdiek F., Nelius N., Benner A., Werft W., Lahrmann B., Grabe N., Schneider M., Tariverdian M., Knebel-Doeberitz M.v., Bläker H., Kloor M.:  Mismatch repair-deficient crypt foci in Lynch syndrome--molecular alterations and association with clinical parameters. PLoS_ONE 10 (3) e121980, 2015.

Vasyutina E., Boucas J.M., Blöhdorn J., Aszyk C., Crispatzu G., Stiefelhagen M., Breuer A., Mayer P., Lengerke C., Döhner H., Beutner D., Rosenwald A., Stilgenbauer S., Hallek M., Benner A., Herling M.:  The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukem. 29 (10) 2003-2014, 2015.

Vichi S., Sandström von Tobel J., Gemma S., Stanzel S., Kopp-Schneider A., Monnet-Tschudi F., Testai E., Zurich M.G.:  Cell type-specific expression and localization of cytochrome P450 isoforms in tridimensional aggregating rat brain cell cultures. Toxicol.in Vitro 30 (1 PART A) 176-184, 2015.

Wagner N.B., Weide B., Reith M., Tarnanidis K., Kehrel C., Lichtenberger R., Pflugfelder A., Herpel E., Eubel J., Ikenberg K., Busch C., Holland-Letz T., Näher H., Garbe C., Umansky V., Enk A., Utikal J., Gebhardt C.:  Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int.J.Cancer 137 (11) 2607-2617, 2015.

Walter D., Lier A., Geiselhart A., Thalheimer F., Huntscha S., Sobotta M., Moehrle B., Brocks D., Bayindir I., Kaschutnig P., Muedder K., Klein C., Jauch A., Schroeder T., Geiger H., Dick T., Holland-Letz T., Schmezer P., Lane S.W., Rieger M., Essers M., Williams D.A., Trumpp A., Milsom M.D.:  Exit from dormancy provokes de novo DNA damage-induced cellular attrition in haematopoietic stem cells. Nature 520 (7548) 549-552, 2015.

Weinhold N., Kirn D., Seckinger A., Hielscher T., Granzow M., Bertsch U., Egerer G., Salwender H., Blau I.W., Weisel K., Hillengass J., Raab M.S., Hose D., Goldschmidt H., Jauch A.:  Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica (epub) , 2015.

Witzens-Harig M., Benner A., McClanathan F., Klemmer J., Brandt J., Brants E., Rieger M., Meissner J., Hensel M., Neben K., Dreger P., Lengfelder E., Schmidt-Wolf I., Krämer A., Ho A.D.:  Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. Br.J.Haematol. 171 (5) 710-719, 2015.

Wrage M., Hagmann W., Kemming D., Uzunoglu F.G., Riethdorf S., Effenberger K., Westphal M., Lamszus K., Kim S.Z., Becker N., Izbicki J.R., Sandoval J., Esteller M., Pantel K., Risch A., Wikman H.:  Identification of HERC5 and its potential role in NSCLC progression. Int.J.Cancer 136 (10) 2264-2272, 2015.

Yang R., Pfütze K., Zucknick M., Sutter C., Wappenschmidt B., Marme F., Qu B., Cuk K., Engel C., Schott S., Schneeweiss A., Brenner H., Claus R., Plass C., Bugert P., Hoth M., Sohn C., Schmutzler R., Bartram C.R., Burwinkel B.:  DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood. Int.J.Cancer 136 (8) 1845-1855, 2015.

Zhan T., Hahn F., Hielscher T., Betge J., Kähler G., Ebert M.P., Belle S.:  Frequent co-occurrence of high-grade dysplasia in large flat colonic polyps (>20 mm) and synchronous polyps. BMC Gastroenterol. 15 82, 2015.

Zucknick M., Saadati M., Benner A.:  Nonidentical twins: Comparison of frequentist and Bayesian lasso for Cox models. Biometr.J. 57 (6) 959-981, 2015.

 

to top